Authors: Marcella Pesce ,Luisa Seguella, Alessandro Del Re, Jie Lu, Irene Palenca, Chiara Corpetti, Sara Rurgo, Walter Sanseverino, Giovanni Sarnelli and Giuseppe Esposito

Institutions:

  • Department of Clinical Medicine and Surgery, University of Naples “Federico II”, 80131 Naples, Italy
  • Department of Physiology and Pharmacology “V. Erspamer”, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy
  • Department of Anatomy and Cell Biology, China Medical University, Shenyang 110122, China
  • Nextbiomics S.r.l., 80100 Naples, Italy

Publication: International Journal of Molecular Sciences 

Date: May 2022

Link:  https://www.mdpi.com/1422-0067/23/10/5466

Abstract:

Engineered probiotics represent a cutting-edge therapy in intestinal inflammatory disease (IBD). Genetically modified bacteria have provided a new strategy to release therapeutically operative molecules in the intestine and have grown into promising new therapies for IBD. Current IBD treatments, such as corticosteroids and immunosuppressants, are associated with relevant side effects and a significant proportion of patients are dependent on these therapies, thus exposing them to the risk of relevant long-term side effects. Discovering new and effective therapeutic strategies is a worldwide goal in this research field and engineered probiotics could potentially provide a viable solution. This review aims at describing the proceeding of bacterial engineering and how genetically modified probiotics may represent a promising new biotechnological approach in IBD treatment.